AI agent skill · by @huang-sir1
Radiology Crossmodal Mapping
Use when an imaging study must map radiology phenotypes or habitats to single-cell, spatial-omics, or pathology-derived cell states across patients, lesions, specimens, regions, or time points. Designs paired, weakly paired, or unpaired cross-modal mapping; audits alignment, deconvolution, label transfer, contrastive learning, validation, scale mismatch, and biological-claim limits. Never treats unpaired public omics as direct patient-level mechanism proof.
Archived 2026-10-23 · Source updated 2026-07-27 · License: MIT. Check the original repository for the latest version.
SKILL.md instructions
# Radiology Cross-Modal Mapping Use this skill when the central problem is how to align an imaging phenotype or habitat with single-cell, spatial-omics, or pathology-derived cellular states. Make the mapping unit and its uncertainty explicit before choosing a method. ## Core stance - Map at the **finest common unit with verified correspondence; coarsen until defensible**. Never promote cohort concordance to patient-, lesion-, region-, or cell-level evidence. - Classify each link as direct, weak, unpaired, or unresolved; separately classify cohort completeness as fully or partially paired. - Treat registration, sampling, timing, treatment, and spatial-scale mismatch as analysis variables, not footnotes. - Audit identity, eligibility, and provenance metadata before splitting; do not use outcomes, biological measurements, or apparent correspondence to resolve links. Then split by patient and, when applicable, center, keeping every fitted step inside training data. ## Required intake Collect the phenotype, assay, anatomy, endpoint, cohorts/centers, hierarchy identifiers, dates, intervening treatment, registration evidence, modality missingness, batch/site variables, intended claim, and validation material. Mark unknown or conflicting links as unresolved. Create a **mapping-unit table** before analysis: | Imaging record | Verified patient | Lesion | Imaging/time | Specimen/section | Region/cell state | Link correspondence | Finest verified common unit | Uncertainty | |---|---|---|---|---|---|---|---|---| | one row per proposed link | ID/none | ID | date/phase | ID(s) | ID/label | direct/weak/unpaired/unresolved | patient/lesion/region | source/magnitude | Add a cohort summary stating eligible counts, modality availability, and whether completeness is fully or partially paired. See [alignment and pairing](references/alignment-and-pairing.md) for definitions, scale mismatch, and permitted inference. ## Workflow 1. **Define the estimand.** State the imaging feature or habitat, cellular state or spatial neighborhood, shared unit, endpoint, direction of mapping, and whether the aim is discovery, prediction, annotation transfer, or biological corroboration. 2. **Audit metadata before splitting.** Using identity, provenance, modality availability, dates, and prespecified eligibility only, trace patient -> lesion -> specimen -> section -> region -> cell. Assign link correspondence and cohort completeness; freeze unresolved links. Do not inspect outcomes, expression, cell states, imaging features, or biological plausibility. 3. **Split, then align.** Split eligible patients and reserve centers when applicable. Apply the prespecified finest common unit with verified metadata correspondence and coarsen until defensible; learn any image-, omics-, or biology-driven alignment in training only. 4. **Choose the mapping route.** Match pseudobulk, deconvolution, canonical correlation, contrastive mapping, graph alignment, or habitat linkage to the link status, scale, and sample size. Transfer labels across imaging and omics only through a paired bridge, shared measured features, or an independently validated cross-modal mapper; otherwise transfer within omics and validate the imaging association separately. 5. **Lock leakage-safe validation.** Keep feature selection, habitat discovery, normalization, anchor learning, label transfer, deconvolution tuning, embedding, graph construction, and threshold selection inside training. Add held-out-center or external validation when transportability is claimed. 6. **Run controls.** Include mapping permutations, biologically implausible or negative regions, null features, method-specific nulls, and site/batch-aware baselines. 7. **Run sensitivity analyses.** Vary registration tolerance, temporal window, aggregation level, habitat definition, cell-state reference, preprocessing, covariates, and borderline links. 8. **Validate biology.** Prefer an independent cohort and orthogonal IHC, multiplex immunofluorescence, in situ hybridization, pathology, or separately measured spatial evidence. 9. **Bound claims.** Tie each conclusion to its link status, cohort completeness, shared unit, validation, and unresolved alternative explanations. Open [mapping and validation](references/mapping-and-validation.md) to select a method and specify patient/center separation, negative controls, sensitivity analyses, external validation, and orthogonal biological validation. ## Output contract Return the applicable components: 1. **`Mapping question`**: phenotype, cell state, purpose, direction, and estimand. 2. **`Mapping-unit table`**: hierarchy, dates, link status, verified common unit, uncertainty. 3. **`Pairing/alignment audit`**: completeness, mismatch, exclusions, permitted inference. 4. **`Mapping plan`**: method, assumptions, preprocessing, covariates, simple baseline. 5. **`Leakage-safe validation`**: patient/center splits and train-only operations. 6. **`Controls/sensitivities`**: nulls and alternative alignment, timing, aggregation, references. 7. **`Validation plan`**: internal, external, orthogonal evidence, success criteria. 8. **`Bounded claims`**: supported wording, prohibited wording, uncertainty, missing inputs. ## Routes - Use `radiology-radiogenomics` when general imaging-omics association, integration, prediction, or biological interpretation is central and cross-scale alignment is not the primary problem. - Route annotation/registration to `radiology-annotation`, inference/resampling to `radiology-stats`, representation design to `radiology-deep-learning`, reporting to `radiology-reporting`, and data provenance/sharing to `radiology-data`. ## Red lines - Do not treat unpaired public omics or a reference atlas as direct patient-level, lesion-level, or mechanistic proof. - Do not call disease-, anatomy-, or time-matched different patients weakly paired; without a shared verified patient key they are unpaired and support cohort-level inference only. - Do not call deconvolved or transferred labels directly measured cells. - Do not transfer labels directly between imaging and omics without a paired bridge, shared measured features, or an independently validated cross-modal mapper. - Reserve **co-localized** for directly registered regional evidence; describe patient- or lesion-level relationships as associated or correlated. - Do not call evaluation independent when a test patient appears in an atlas, mapper-training set, or pretrained reference. Exclude the overlap or label the evaluation non-independent/model-exposed. - Do not mix cells, regions, lesions, or time points from one patient across training and test sets. - Do not fit habitats, anchors, embeddings, thresholds, or feature selection on held-out data. - Do not use causal or therapeutic language without an appropriate causal or experimental design. - Never invent identifiers, pairings, registration quality, biological associations, validation results, or missing metadata.